LONDON–(BUSINESS WIRE)–#AlprazolamMarket–The alprazolam market is poised to grow by USD 90.33 million during 2020-2024, progressing at a CAGR of over 4% during the forecast period. Request free sample pages
Read the 159-page report with TOC on “Alprazolam Market Analysis Report by Type (anxiety, panic disorders, and others) and Geographic Landscape (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2020-2024.”
https://www.technavio.com/report/global-alprazolam-market-industry-analysis
The market is driven by the increasing prevalence of anxiety disorders. In addition, the use of alprazolam in new research areas is anticipated to boost the growth of the alprazolam market.
The middle-aged and older population are more likely to experience psychiatric indications such as anxiety and panic disorders. In addition, the prevalence of anxiety and panic disorders is also on the rise among the younger population due to hectic lifestyles. These factors have led to a rise in the number of awareness campaigns focused on ensuring timely diagnosis and treatment of these indications. All these factors are expected to drive the demand for alprazolam.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Alprazolam Companies:
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. operates the business across segments such as Generics and Specialty. Generic Xanax(R) XR Extended Release Tablets is one of the key offerings of the company. It is an alprazolam-based generic version of XANAX XR, which is approved for the management of anxiety or the short-term relief from the symptoms of anxiety. The company offers the drug in four different doses, namely 0.5 mg, 1 mg, 2 mg, and 3 mg.
Cadila Healthcare Ltd.
Cadila Healthcare Ltd. operates the business in the Pharmaceuticals segment. Alprazolam tablet is one of the key offerings of the company. It is a short-acting benzodiazepine that is approved for the treatment of panic disorders and anxiety. The company offers the drug in three doses, namely 0.5mg, 1mg, and 2mg.
Endo International Plc
Endo International Plc operates the business across various segments such as US Branded – Specialty & Established Pharmaceuticals, US Branded – Sterile Injectables, US Generic Pharmaceuticals, and International Pharmaceutical. Niravam is the key offering of the company, which is an alprazolam-based drug that is used for the treatment of anxiety and panic disorders. The drug is available in four dosage forms, 0.25mg, 0.5mg, 1mg, and 2mg.
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc operates the business under the unified business segment. The key offering of the company comprises of a benzodiazepine-based drug that is approved for the treatment of generalized anxiety disorder and panic disorder, with or without agoraphobia.
Mylan NV
Mylan NV operates the business across segments such as Gx, Rx/Bx, and OTC. ALPRAZOLAM Tablets, USP is the key offering of the company. It is a benzodiazepine-based drug that is approved for the treatment of anxiety and panic disorders. The company offers the drug in four doses, 0.25mg, 0.5mg, 1mg, and 2mg.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
Alprazolam Market Type Outlook (Revenue, USD mn, 2020-2024)
- Anxiety
- Panic disorders
- Others
Alprazolam Market Geographic Landscape Outlook (Revenue, USD mn, 2020-2024)
- Asia
- Europe
- North America
- ROW
- Key leading countries
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
